Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $498,098.81 in Stock

Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) CFO Oluyemi Okupe sold 11,581 shares of the company’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $43.01, for a total value of $498,098.81. Following the completion of the transaction, the chief financial officer now owns 107,789 shares of the company’s stock, valued at $4,636,004.89. The trade was a 9.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

  • On Tuesday, February 4th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $38.92, for a total value of $450,732.52.
  • On Monday, January 13th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The shares were sold at an average price of $24.44, for a total value of $283,039.64.
  • On Thursday, December 26th, Oluyemi Okupe sold 4,213 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.98, for a total value of $126,305.74.
  • On Friday, December 20th, Oluyemi Okupe sold 18,959 shares of Hims & Hers Health stock. The shares were sold at an average price of $25.77, for a total value of $488,573.43.
  • On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total value of $3,021,032.66.
  • On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.

Hims & Hers Health Trading Up 28.4 %

Hims & Hers Health stock opened at $59.49 on Friday. The firm has a market capitalization of $13.00 billion, a P/E ratio of 135.20 and a beta of 1.35. Hims & Hers Health, Inc. has a 1 year low of $9.22 and a 1 year high of $59.55. The business has a 50-day moving average of $31.53 and a 200-day moving average of $23.99.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently modified their holdings of HIMS. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after purchasing an additional 4,145,305 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares in the last quarter. Yong Rong HK Asset Management Ltd bought a new position in shares of Hims & Hers Health during the 4th quarter valued at about $41,104,000. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after purchasing an additional 1,562,302 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company’s stock valued at $30,878,000 after purchasing an additional 1,098,148 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HIMS has been the subject of a number of analyst reports. TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. BTIG Research initiated coverage on Hims & Hers Health in a report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Canaccord Genuity Group raised their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. Deutsche Bank Aktiengesellschaft raised their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.13.

Check Out Our Latest Stock Report on HIMS

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Featured Stories

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.